Nautilus Biotechnolgy
NAUT
68 hedge funds and large institutions have $48.9M invested in Nautilus Biotechnolgy in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 29 reducing their positions, and 12 closing their positions.
13% more capital invested
Capital invested by funds: $43.3M → $48.9M (+$5.6M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.53% less ownership
Funds ownership: 47.37% → 45.84% (-1.5%)
4% less funds holding
Funds holding: 71 → 68 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
72% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$285K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$128K |
| 3 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$110K |
| 4 |
CA
Crewe Advisors
Salt Lake City,
Utah
|
+$100K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$60.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
-$451K |
| 2 |
BlackRock
New York
|
-$314K |
| 3 |
ST
Sentinel Trust
Houston,
Texas
|
-$203K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$163K |
| 5 |
Goldman Sachs
New York
|
-$145K |
NAUT Hedge Fund Activity: Q3 2025 in Review
68 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q3 2025, worth a combined $48.9M — up 13% from $43.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NAUT and 9 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $285K. The largest seller was ArchPoint Investors, exiting entirely with an estimated $451K sold.
- 68 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q3 2025, down from 71 in Q2 2025.
- Funds reported $48.9M of Nautilus Biotechnolgy stock for Q3 2025, up 13% quarter-over-quarter.
- 9 funds opened new Nautilus Biotechnolgy positions in Q3 2025 and 12 closed out, a net change of -3 holders.
- The largest Nautilus Biotechnolgy buyer in Q3 2025 was Renaissance Technologies, an estimated $285K added.
- The largest Nautilus Biotechnolgy seller in Q3 2025 was ArchPoint Investors, an estimated $451K sold.
Based on aggregated 13F filings for Q3 2025.